| answer text |
<p>Clinically eligible cohorts have been determined by an independent expert group
commissioned by the Department and included in a clinical policy agreed by the United
Kingdom Chief Medical Officers. The cohorts include patients whose immune systems
mean they are at higher risk of COVID-19, such as organ transplant patients or those
recently undergoing chemotherapy or radiotherapy. This policy was based on evidence
that certain health conditions can make a patient much more likely to progress to
severe disease. As a result, these patients could benefit the most from these novel
medications. People with muscular dystrophy are not currently identified as part of
this eligible cohort.</p><p>The Therapeutics Clinical Review Pane, which was established
to focus on at-risk patient cohorts that could be eligible for COVID-19 therapies,
including providing advice on cohorts, can consider specific queries from clinicians
and patient groups supported by clinicians, including on eligibility and conditions
like muscular dystrophy.</p>
|
|
